Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for High Risk Mild COVID-19
NCT04504032Phase 2Terminated
- Sponsor
- Gates Medical Research Institute
- Start
- Sep 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of rivaroxaban in coronavirus disease 2019 (COVID-19), sponsored by Gates Medical Research Institute. Started Sep 2020; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04504032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504032.